Literature DB >> 20670652

Clinical impact of methicillin resistance on outcome of patients with Staphylococcus aureus infection: a stratified analysis according to underlying diseases and sites of infection in a large prospective cohort.

Cheol-In Kang1, Jae-Hoon Song, Doo Ryeon Chung, Kyong Ran Peck, Kwan Soo Ko, Joon-Sup Yeom, Shin-Woo Kim, Hyun-Ha Chang, Yeon-Sook Kim, Sook-In Jung, Jun Seong Son, Po-Ren Hsueh, Thomas Man-kit So, M K Lalitha, Yonghong Yang, Shao-Guang Huang, Hui Wang, Quan Lu, Celia C Carlos, Jennifer A Perera, Cheng-Hsun Chiu, Jien-Wei Liu, Anan Chongthaleong, Visanu Thamlikitkul, Hung Van Pham.   

Abstract

OBJECTIVE: This study was conducted to identify the predictors of mortality and to evaluate the impact of methicillin resistance on outcome in patients with Staphylococcus aureus infection according to underlying conditions and type of infection.
METHODS: An observational cohort study including 4949 patients with S. aureus infection was conducted. We compared data from patients with MRSA infection with those with MSSA infection.
RESULTS: The 30-day mortality rate of MRSA group was significantly higher than that of MSSA group (15.6% vs. 6.2%, P < 0.001). However, MRSA infection was not found to be independent risk factor for mortality after adjusting for other variables (OR = 1.03, 95% CI = 0.80-1.32). When we analyzed patients with S. aureus bacteremia (n = 709), MRSA infection was found to be significantly associated with mortality in multivariate analysis (Adjusted OR = 1.69, 95% CI = 1.15-2.49). When the 30-day mortality rates were compared according to underlying diseases, the 30-day mortality rate of MRSA group was significantly higher than that of MSSA group in patients with malignancy or renal diseases. MRSA infection was also found to be one of the independent risk factors for mortality in patients with malignancy (adjusted OR = 1.69, 95% CI = 1.06-2.70) and in those with renal disease (adjusted OR = 1.70, 95% CI = 1.0-2.89), after adjustment for host variables.
CONCLUSIONS: Methicillin resistance adversely affected the outcome of patients with S. aureus infection, in patients with cancer or renal disease and in those with S. aureus bacteremia, although MRSA infection was not found to be significantly associated with higher mortality in overall patient population.
Copyright © 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670652     DOI: 10.1016/j.jinf.2010.07.011

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  17 in total

1.  Reduced pro-inflammatory responses to Staphylococcus aureus bloodstream infection and low prevalence of enterotoxin genes in isolates from patients on haemodialysis.

Authors:  S McNicholas; A Fe Talento; J O'Gorman; M M Hannan; M Lynch; C M Greene; P J Conlon; A C Shore; D C Coleman; H Humphreys; D Fitzgerald-Hughes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-09       Impact factor: 3.267

2.  Empirical combination of a β-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to vancomycin monotherapy.

Authors:  G E Park; J-H Ko; S Y Cho; Y E Ha; N Y Lee; C-I Kang; D R Chung; J-H Song; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-11       Impact factor: 3.267

3.  Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients.

Authors:  Cheol-In Kang; Jae-Hoon Song; Kwan Soo Ko; Doo Ryeon Chung; Kyong Ran Peck
Journal:  Support Care Cancer       Date:  2011-02-12       Impact factor: 3.603

Review 4.  Predictors of mortality in Staphylococcus aureus Bacteremia.

Authors:  Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

5.  Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.

Authors:  S Pollett; S M Baxi; G W Rutherford; S B Doernberg; P Bacchetti; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

6.  Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study.

Authors:  Carlos Seas; Coralith Garcia; Mauro J Salles; Jaime Labarca; Carlos Luna; Carlos Alvarez-Moreno; Carlos Mejía-Villatoro; Jeannete Zurita; Manuel Guzmán-Blanco; Eduardo Rodríguez-Noriega; Jinnethe Reyes; Cesar A Arias; Cesar Carcamo; Eduardo Gotuzzo
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

7.  Colonization with antibiotic-susceptible strains protects against methicillin-resistant Staphylococcus aureus but not vancomycin-resistant enterococci acquisition: a nested case-control study.

Authors:  Susan S Huang; Rupak Datta; Sheryl Rifas-Shiman; Ken Kleinman; Hilary Placzek; Julie D Lankiewicz; Richard Platt
Journal:  Crit Care       Date:  2011-09-14       Impact factor: 9.097

8.  Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study.

Authors:  Kuo-Sheng Liu; Cheng-Hung Lee; Yi-Chuan Wang; Shih-Jung Liu
Journal:  Int J Nanomedicine       Date:  2015-01-29

Review 9.  Antimicrobial resistance in Asia: current epidemiology and clinical implications.

Authors:  Cheol-In Kang; Jae-Hoon Song
Journal:  Infect Chemother       Date:  2013-03-29

10.  Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study.

Authors:  Hea Sung Ok; Hyoun Soo Lee; Man Je Park; Ki Hoon Kim; Byeong Ki Kim; Yu Mi Wi; June Myung Kim
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.